Repositioning Candidate Details

Candidate ID: R0775
Source ID: DB05340
Source Type: investigational
Compound Type: small molecule
Compound Name: ATL-2502
Synonyms: --
Molecular Formula: C28H31NaO9S
SMILES: [Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O
Structure:
DrugBank Description: ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
CAS Number: --
Molecular Weight: 566.595
DrugBank Indication: Investigated for use/treatment in inflammatory bowel disease and ulcerative colitis.
DrugBank Pharmacology: --
DrugBank MoA: ATL-2502 is the combination of Alizyme's proprietary colonic drug delivery system, colal, and prednisolone metasulfobenzoate sodium ("PMSBS"), an approved steroid in Europe. colal-PRED has a starch coating that is only broken down in the gut by bacteria occurring in the colon. This leads to topical delivery of PMSBS to the colon rather than systemic delivery with the objective of providing efficacy, but without the side effects of steroids; however, the efficacy and safety of colal-PRED must be shown in well-controlled, prospective clinical trials and approved by the FDA.
Targets: --
Inclusion Criteria: Therapeutic strategy associated